Skip to main navigation Skip to search Skip to main content

Pazopanib as a new culprit in neutrophilic eccrine hidradenitis

  • Fang Ying Wang
  • , Wei Ti Chen
  • , Meng Han Shen
  • , Wen Hung Chung
  • , Chun Bing Chen

Research output: Contribution to journalArticlepeer-review

Abstract

Neutrophilic eccrine hidradenitis (NEH) usually manifests as asymptomatic or painful infiltrated erythematous papules or plaques of variable sizes. It is characterized by dense neutrophilic infiltration and necrosis of the eccrine secretory coils in histopathology. The condition is most commonly reported in patients with hematologic malignancy, who have been undergoing chemotherapy. Direct drug toxicity to the eccrine glands has been proposed to be the cause of NEH. Although several drugs have been reported to induce NEH, the tyrosine kinase inhibitors have only rarely been identified as culprits in the literature. Here, we present a case of pazopanib-related NEH in a patient with uterine adenocarcinoma, in which NEH recurred after the reintroduction of pazopanib. To the best of our knowledge, this is the first report of a case of pazopanib-related NEH.

Original languageEnglish
Pages (from-to)222-225
Number of pages4
JournalDermatologica Sinica
Volume37
Issue number4
DOIs
Publication statusPublished - Oct 1 2019
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Neutrophilic eccrine hidradenitis
  • pazopanib
  • tyrosine kinase inhibitor
  • uterine adenocarcinoma

ASJC Scopus subject areas

  • Dermatology

Fingerprint

Dive into the research topics of 'Pazopanib as a new culprit in neutrophilic eccrine hidradenitis'. Together they form a unique fingerprint.

Cite this